Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Ultragenyx Pharmaceutical Inc (RARE)  
$42.75 0.45 (1.04%) as of 4:30 Fri 5/3


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 82,110,000
Market Cap: 3.51(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $31.73 - $53.69
Level I Sector: Consumer Discretionary
Level II Sector: Leisure
Level III Sector: Restaurants

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ COMPOSITE
    NASDAQ INDUSTRIAL     S&P SMALLCAP 600
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 69,133 99,133 200,384 249,340
Total Sell Value $3,373,178 $4,809,278 $8,291,909 $10,478,837
Total People Sold 8 8 9 12
Total Sell Transactions 10 11 20 34
End Date 2024-02-04 2023-11-03 2023-05-05 2022-05-05

   
Records found: 628
  Page 9 of 26  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Kassberg Thomas Richard CBO & EVP   •       –      –    2020-10-14 4 S $87.98 $23,051 D/D (262) 101,478 -54%     
   Huang Dennis Karl EVP & Chief Tech Ops Officer   •       –      –    2020-10-14 4 S $88.00 $23,056 D/D (262) 34,699 -54%     
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-10-14 4 S $88.00 $28,600 D/D (325) 23,968 -54%     
   Sharp Shalini EVP, Finance   •       –      –    2020-10-14 4 S $87.99 $32,996 D/D (375) 97,812 -54%     
   Pinion John Richard See Remarks   •       –      –    2020-10-12 4 AS $94.47 $262,627 D/D (2,780) 46,561 52%     
   Dier Mardi CFO & Executive Vice President   •       –      –    2020-10-12 4 A $0.00 $0 D/D 40,000 40,000     -
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-10-08 4 AS $95.00 $950,000 D/D (10,000) 24,293 57%     
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-10-08 4 OE $54.50 $545,000 D/D 10,000 34,293     -
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-10-06 4 AS $90.00 $900,000 D/D (10,000) 24,293 61%     
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-10-06 4 OE $48.43 $484,300 D/D 10,000 34,293     -
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-09-23 4 AS $85.00 $850,000 D/D (10,000) 24,293 87%     
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-09-23 4 OE $48.43 $484,300 D/D 10,000 34,293     -
   Kakkis Emil D President & CEO   •       •      –    2020-09-01 4 AS $82.63 $2,478,900 I/I (30,000) 2,389,741 64%     
   Aliski William Director   –       •      –    2020-08-21 4 S $86.57 $432,850 D/D (5,000) 57,018 -54%     
   Aliski William Director   –       •      –    2020-08-21 4 OE $58.74 $293,700 D/D 5,000 62,018     -
   Sharp Shalini CFO & Executive Vice President   •       –      –    2020-08-17 4 S $88.24 $1,271,073 D/D (14,378) 98,187 -68%     
   Sharp Shalini CFO & Executive Vice President   •       –      –    2020-08-17 4 OE $48.43 $698,524 D/D 11,357 101,856     -
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-08-17 4 S $88.39 $1,093,884 D/D (12,370) 24,293 -68%     
   Parschauer Karah Herdman EVP and General Counsel   •       –      –    2020-08-17 4 OE $54.50 $545,000 D/D 10,000 36,663     -
   Siegall Clay B Director   –       •      –    2020-08-10 4 S $85.01 $964,523 D/D (11,346) 2,550 -97%     
   Siegall Clay B Director   –       •      –    2020-08-10 4 OE $40.37 $64,431 D/D 1,596 4,146     -
   Siegall Clay B Director   –       •      –    2020-08-07 4 S $85.55 $2,002,212 D/D (23,404) 12,300 -98%     
   Siegall Clay B Director   –       •      –    2020-08-07 4 OE $21.00 $605,844 D/D 23,404 35,704     -
   Kakkis Emil D President & CEO   •       •      –    2020-07-13 4 AS $85.35 $3,414,000 I/I (40,000) 2,419,741 40%     
   Huizenga Theodore Alan SVP, Controller and PAO   •       –      –    2020-07-08 4 AS $91.00 $240,058 D/D (2,638) 16,582 33%     
  628 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 9 of 26
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us